High CD133 expression levels in gastrointestinal stromal tumors

Background: Gastrointestinal stromal tumours (GISTs) have activating KIT or PDGFRA gene mutations. Imatinib mesylate, which targets KIT and PDGFRA, is effective in treating GISTs, but 90% of GIST patients become imatinib‐resistant as a result of acquiring secondary KIT mutations. Recent findings sug...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cytometry. Part B, Clinical cytometry Clinical cytometry, 2011-07, Vol.80B (4), p.238-247
Hauptverfasser:	Bozzi, Fabio, Conca, Elena, Manenti, Giacomo, Negri, Tiziana, Brich, Silvia, Gronchi, Alessandro, Pierotti, Marco A., Tamborini, Elena, Pilotti, Silvana
Format:	Artikel
Sprache:	eng
Schlagworte:	AC133 Antigen Animals Antigens, CD - genetics Antigens, CD - metabolism Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Benzamides cancer stem cells CD133 Cell Line Drug Resistance, Neoplasm Female Gastrointestinal Stromal Tumors - drug therapy Gastrointestinal Stromal Tumors - metabolism Gastrointestinal Stromal Tumors - secondary gastrointestinal stromal tumours Glycoproteins - genetics Glycoproteins - metabolism Humans imatinib Imatinib Mesylate Immunophenotyping Mice Mice, Nude Mutation Neoplasm Transplantation Neoplastic Stem Cells - metabolism Peptides - genetics Peptides - metabolism Piperazines - pharmacology Piperazines - therapeutic use Proto-Oncogene Proteins c-kit - genetics Proto-Oncogene Proteins c-kit - metabolism Pyrimidines - pharmacology Pyrimidines - therapeutic use Thy-1 Antigens - genetics Thy-1 Antigens - metabolism Transcription, Genetic Transplantation, Heterologous Tumor Cells, Cultured
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!